Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other menin
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Gainers
Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition